Charlene Rae

Charlene Rae

Auto-generated profile, based on publicly available information

Charlene Rae

Department of Pediatrics McMaster University Hamilton Ontario Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
WFWilliam Furlong
William Furlong
CRCharlene Rae
Charlene Rae
DFDavid Feeny
David Feeny
RGRichard D. Gelber
Richard D. Gelber
CLCaroline Laverdiere
Caroline Laverdiere
RBRonald Barr
Ronald Barr

21 September 2012 in Haemophilia
Verified
Journal Article
Closed access
PDF file
CRC. Rae
C. Rae
WFW. Furlong
W. Furlong
JHJ. Horsman
J. Horsman
EPE. Pullenayegum
E. Pullenayegum
CDC. Demers
C. Demers
RBR. Barr
R. Barr

23 June 2021 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
PPPandora Patterson
Pandora Patterson
NDNorma M. D'Agostino
Norma M. D'Agostino
FMFiona McDonald
Fiona McDonald
TCTerry David Church
Terry David Church
DCDaniel S. J. Costa
Daniel S. J. Costa
IGInternational AYA Cancer Distress Screening Group
International AYA Cancer Distress Screening Group
Objective: Adolescents and young adults (AYAs) diagnosed with cancer commonly experience elevated psychological distress and need appropriate detection and management of the psychosocial impact of their illness and treatment. This paper describes the multinational validation of the Distress Thermometer (DT) for AYAs recently diagnosed with cancer and the relationship between distress and patient concerns on the AYA‐Needs Assessment (AYA‐NA).Methods: AYA patients (N = 288; 15–29 years, Mage = 21.5 years, SDage = 3.8) from Australia (n = 111), Canada (n = 67), the UK (n = 85) and the USA (n = 25) completed the DT, AYA‐NA, Hospital Anxiety Depression Scale (HADS) and demographic measures within 3 months of diagnosis. Using the HADS as a criterion, receiver operating characteristics analysis was used to determine the optimal cut‐off score and meet the acceptable level of 0.70 for sensitivity and specificity. Correlations between the DT and HADS scores, prevalence of distress and AYA‐NA scores were reported.Results: The DT correlated strongly with the HADS‐Total, providing construct validity evidence (r = 0.65, p < 0.001). A score of 5 resulted in the best clinical screening cut‐off on the DT (sensitivity = 82%, specificity = 75%, Youden Index = 0.57). Forty‐two percent of AYAs scored at or above 5. ‘Loss of meaning or purpose’ was the AYA‐NA item most likely to differentiate distressed AYAs.Conclusions: The DT is a valid distress screening instrument for AYAs with cancer. The AYA‐POST (DT and AYA‐NA) provides clinicians with a critical tool to assess the psychosocial well‐being of this group, allowing for the provision of personalised support and care responsive to individuals' specific needs and concerns.

1 March 2007 in Landscape and Urban Planning
Verified
Journal Article
Closed access
CRCharlene Rae
Charlene Rae
KRKristina Rothley
Kristina Rothley
Suzana DragicevicSuzana Dragicevic
Suzana Dragicevic

1 November 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CSClaire R. Stewart
Claire R. Stewart
LALeah Algu
Leah Algu
RKRakhshan Kamran
Rakhshan Kamran
CLCameron F. Leveille
Cameron F. Leveille
KAKhizar Abid
Khizar Abid
SLShari R Lipner
Shari R Lipner

1 June 2005 in Environmental Modeling & Assessment
Verified
Journal Article
Closed access
PDF file
KRKristina D. Rothley
Kristina D. Rothley
CRCharlene Rae
Charlene Rae